Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
MWN-AI** Summary
Can-Fite BioPharma Ltd. (NYSE American: CANF) recently announced that it has received a notice of allowance for Canadian Patent Application No. 3,126,002, which pertains to Namodenoson, its orally bioavailable A3 adenosine receptor (A3AR) agonist, as an anti-obesity therapy. This patent covers innovative methods for utilizing Namodenoson to reduce fat mass and body weight, expanding Can-Fite’s intellectual property in Canada, where it already holds patents in the U.S. and Australia for this application.
Namodenoson is currently in clinical trials for multiple indications, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and various cancer treatments. Key findings reveal that Namodenoson administration has led to a significant reduction in fat levels in fat cells and body weight in obesity-model studies. In a Phase IIa study for MASH, patients experienced a 2.3% weight loss after three months, along with raised levels of adiponectin, a hormone essential for fat regulation.
With the global obesity treatment market projected to escalate to $60.5 billion by 2030 at a compound annual growth rate (CAGR) of around 22%, the announcement positions Can-Fite strategically within a burgeoning sector. Dr. Pnina Fishman, Can-Fite’s CSO, emphasized that the new patent could open significant development and partnership opportunities, underscoring the long-term value of their A3 adenosine receptor platform.
Overall, as Can-Fite continues to evolve its clinical portfolio, the recognition of Namodenoson as a potential anti-obesity therapy enhances both its credibility and strategic position in the pharmaceutical industry, targeting a market defined by increasing demand for effective oral therapies.
MWN-AI** Analysis
Can-Fite BioPharma Ltd. (NYSE American: CANF) has recently received a patent allowance in Canada for its anti-obesity therapy, Namodenoson, which enhances its intellectual property portfolio as it seeks to penetrate the burgeoning obesity treatment market. With the global obesity market projected to reach $60.5 billion by 2030, presenting a CAGR of around 22%, Can-Fite is well-positioned to leverage the increasing prevalence of obesity and the demand for new therapeutic approaches.
Namodenoson, an A3 adenosine receptor agonist, has shown a favorable safety profile and efficacy in reducing fat mass and body weight in various trials. In animal models, it effectively reduced fat levels and increased serum adiponectin, a crucial hormone for fat regulation. The promising results from the Phase IIa MASH study emphasize its potential dual utility in treating both obesity and liver conditions.
Investors should closely monitor Can-Fite’s advancements as the company progresses through its various clinical trials, including the pivotal Phase III for advanced liver cancer and the ongoing studies for MASH and pancreatic cancer. Successful outcomes could catalyze a significant positive market revaluation. Furthermore, the strategic expansion of its product pipeline not only diversifies its therapeutic focus but also enhances the company's attractiveness for potential partnerships and collaborations within the biotechnology sector.
However, prospective investors should remain cautious. The biotechnology landscape carries inherent risks, including regulatory uncertainties and capital requirements for continued development. Additionally, external pressures such as geopolitical tensions and economic conditions could impact operational stability.
In summary, Can-Fite presents a compelling investment opportunity given its innovative approach to addressing obesity and metabolic disorders, coupled with robust clinical data. Investors should keep a keen eye on upcoming trial results and developments within the competitive landscape of obesity treatments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market
Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled “An A3 adenosine receptor ligand for use for achieving a fat loss effect.
The patent covers the use of Namodenoson, Can-Fite’s orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy.
Can-Fite already holds corresponding patents in the United States and Australia for the use of Namodenoson in obesity and metabolic disorders. Namodenoson is currently in clinical development for Metabolic Dysfunction-Associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer, and has demonstrated an excellent safety profile across multiple clinical studies following oral administration.
The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet. In a MASH Phase IIa study, in patients treated with Namodenoson, a 2.3% weight loss has been observed after 3 months with a significant increase in serum adiponectin levels.
“Expanding our intellectual property estate into metabolic indications such as fat loss creates new development and partnering opportunities and reinforces the long-term value of our A3 adenosine receptor platform,” said Pnina Fishman, Ph.D., Can-Fite CSO and Chairperson.
The global obesity treatment market is projected to reach $60.5 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 22%, driven by increasing disease prevalence and demand for safe, effective oral therapies.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), and in a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
+972-3-9241114
FAQ**
What specific oral safety assessments have been conducted for Namodenoson to support its favorable safety profile as reported in clinical studies involving Can-Fite Biopharma Ltd Sponsored ADR CANF?
How does the metabolic activity of Namodenoson, particularly its effect on adiponectin levels, enhance its potential effectiveness as an anti-obesity treatment in the market?
Can you provide insights into the long-term safety and efficacy of Namodenoson in diverse populations, particularly considering its use as an oral therapy by Can-Fite Biopharma Ltd Sponsored ADR CANF?
What mechanisms does Namodenoson employ to regulate fat production in the body, and how does this distinguish it from other obesity treatments currently in development by companies including Can-Fite Biopharma Ltd Sponsored ADR CANF?
**MWN-AI FAQ is based on asking OpenAI questions about Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) (NYSE: CANF).
NASDAQ: CANF
CANF Trading
4.24% G/L:
$3.07 Last:
26,347,625 Volume:
$3.65 Open:
